How Does Finasteride Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Finasteride Works
- Primary Action: Inhibits type II 5α‑reductase enzyme
- Chemical Effect: Reduces dihydrotestosterone (DHT) by ~70% in serum
- Physiological Result: Slows hair follicle miniaturisation, prolongs growth phase
- Onset of Action: DHT drop within 24‑48 hours; visible hair improvement takes 3‑6 months
- Dependency: Requires daily use to maintain suppressed DHT levels
- Selectivity: Does not bind to androgen receptors; only blocks DHT production
Finasteride works by specifically inhibiting the 5α‑reductase enzyme, which converts testosterone into the more potent androgen dihydrotestosterone (DHT). By lowering DHT levels in the scalp, it helps reverse the follicular miniaturisation that leads to male pattern baldness.
Important Medical Advice
Finasteride is not suitable for women or children. If you experience breast lumps, pain, nipple discharge, or signs of an allergic reaction (rash, swelling, difficulty breathing), stop taking finasteride and consult a doctor immediately. Always discuss any new medication with your GP or pharmacist.
Chemical Composition & Molecular Structure
Finasteride is a synthetic 4‑azasteroid compound specifically designed to inhibit 5α‑reductase.
Chemical Structure Details
N‑(1,1‑dimethylethyl)‑3‑oxo‑4‑aza‑5α‑androst‑1‑ene‑17β‑carboxamide
This steroidal backbone mimics testosterone but contains a nitrogen atom in the A‑ring, giving it high affinity for 5α‑reductase.
C23H36N2O2
23 carbon, 36 hydrogen, 2 nitrogen, and 2 oxygen atoms.
372.55 g/mol
Relatively small lipophilic molecule, allowing good tissue penetration.
Key Pharmaceutical Properties
| Property | Value | Clinical Significance |
|---|---|---|
| Solubility | Freely soluble in ethanol, slightly soluble in water | Lipophilic nature aids absorption |
| pKa | ~13 (very weak acid) | Essentially unionised at physiological pH |
| Protein Binding | Approximately 90% (mainly albumin) | High binding contributes to long half‑life |
| Selectivity | >100‑fold for type II 5α‑reductase vs type I | Explains scalp DHT reduction |
🗒️ Pharmaceutical Insight: The 4‑azasteroid structure is crucial – the nitrogen atom in the A‑ring forms a stable transition‑state mimic with NADP+, making finasteride a potent, slowly reversible inhibitor.
Mechanism of Action: How Finasteride Blocks DHT
Finasteride reduces DHT by interfering with its synthesis, not by blocking androgen receptors.
Normal DHT Production Pathway
- Testosterone circulates and enters target cells.
- 5α‑reductase converts testosterone to DHT.
- DHT binds androgen receptors with 5× higher affinity, triggering miniaturisation.
Finasteride’s Intervention
| Step | Normal Process | With Finasteride |
|---|---|---|
| 1. Enzyme binding | 5α‑reductase freely converts testosterone to DHT | Finasteride competes, forming stable complex |
| 2. DHT production | High DHT levels | DHT synthesis reduced by 60‑70% in serum |
| 3. Androgen receptor activation | Excessive DHT drives miniaturisation | Lower DHT, follicles can recover |
🗒️ Physiological Insight: Finasteride does not affect testosterone levels significantly – they may even rise slightly. This maintains normal male characteristics.
Enzyme Inhibition: Targeting 5‑Alpha Reductase
Finasteride is a competitive, slowly reversible inhibitor of type II 5α‑reductase.
Inhibition Characteristics
Slow, tight‑binding inhibition
Forms irreversible‑like complex
4.2 nM (type II)
Extremely potent against type II
~30 days for enzyme activity
New enzyme synthesis required
Metabolic Effects and Duration in the Body
Primary Metabolism
Liver (CYP3A4) – oxidation, glucuronidation
Elimination
57% faeces, 39% urine; half‑life 6‑8h
Tissue Distribution
Volume 76 L; crosses BBB minimally
- 1‑2h: Peak plasma
- 24h: serum DHT ↓70%
- 7d: max suppression
- 3‑6m: visible results
- after stop: DHT returns within 14d
Absorption, Distribution & Elimination
Absorption
Bioavailability 80% , Tmax 1‑2h
Distribution
Volume 76 L, protein binding 90%
Elimination
Half‑life 6‑8h; renal 39% metabolites
Clinical Efficacy for Hair Loss
Finasteride 1mg daily is proven to halt hair loss and promote regrowth.
| Outcome | Finasteride 1mg (2y) | Placebo |
|---|---|---|
| Hair count (vertex) | +86 hairs | -19 hairs |
| Self‑assessment improved | 65% | 20% |
Finasteride Mechanism FAQs
How does finasteride differ from minoxidil?
Finasteride reduces DHT to stop follicular miniaturisation, while minoxidil is a vasodilator stimulating hair growth directly.
Does finasteride affect testosterone levels?
Serum testosterone may increase by 10‑20% because less is converted to DHT. This remains within normal range.
How quickly does DHT drop after starting finasteride?
Serum DHT falls by about 70% within 24‑48 hours of the first dose. Scalp DHT reduction takes a few more days.
Why does finasteride not affect body hair?
Body hair growth is driven more by testosterone than DHT. Finasteride leaves testosterone levels unchanged.
Can finasteride be used indefinitely?
Yes, finasteride is safe for long‑term use. Benefits continue as long as you take it; stopping will reverse effects.
Need a Prescription for Finasteride?
If you're experiencing male pattern hair loss, speak with a UK‑registered doctor through a confidential online consultation.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered | Discreet packaging | UK‑registered doctors
Start Hair Loss ConsultationRelated Finasteride Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 15 February 2026
Next Review: 15 August 2026
Published on: 15 February 2026
Last Updated: 15 February 2026